Introduction:

Short Bowel Syndrome Market was valued at US$ 850.5 million in 2024 and is projected to grow at a CAGR of 13.7% to reach US$ 3060.8 million by 2034.

Short bowel syndrome is related to poor motility, poor absorption of nutrients, and movement inside the intestine, generally occurs in people who have had at least half of their small intestine or partially short bowel syndrome is related to poor motility, poor absorption of nutrients, and movement inside the intestine, generally occurs in people who have had at least half of their small intestine or partially part of large intestine removed. It can be mild, moderate and severe in people, depending on small intestine functions. Moreover, people suffering from short bowel syndrome cannot absorb minerals, calories, protein, vitamins, fat, and enough water from food. Short bowel syndrome is caused due to factors such as intestinal diseases, intestinal injuries, and birth defects. At present, there is no cure for short bowel syndrome and the treatment is targeted towards symptoms. Therefore, the pharmaceutical industry is constantly involved in the research and developmental activity and in turn, it is expected to gain more share value during the forecast period.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

As per the Crohn’s& Colitis Foundation of America, approximately 10,000-20,000 people were suffered from short bowel syndrome in 2010. In addition to this, around 25% people reported with other complication within two years. Due to insufficient nutrients to the body, the rate of absorption decreased and many children suffered and died due to malnutrition. Increasing awareness due to the rapid improvements in healthcare and accessibility of epidemiological data to manage better short bowel disease in coming years. Besides, the state government in association with non-profit organizations offering grants and funds to manufacturers for the research and development of short bowel syndrome therapeutics. Hence, it is projected to attain significant market growth within the forecast period.

The short bowel syndrome market has been segmented on the basis of drug type, distribution channel, and region.

The drug type segment includes anti-diarrheals, proton pump inhibitors, histamine blockers, growth hormone, glucagon-like peptide, and others.

On the basis of the distribution channel, the global short bowel syndrome market has been segmented into specialty pharmacies, hospital pharmacies, and others.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Short Bowel Syndrome Market Regional Insights

On the basis of region, the global short bowel syndrome market has been segmented into North America, Latin America, Asia Pacific, Europe, Middle East and Africa. North America dominates the market due to large pool of people adopting drugs and requiring new treatment options. Asia-Pacific is expected to register faster growth over the forecast period due to major players in the market, huge R&D infrastructure and investment.

Report Scope:

Attribute	Details
Market Size 2024	US$ 850.5 million
Projected Market Size 2034	US$ 3060.8 billion
CAGR Growth Rate	13.7.0%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Drug Type - Anti-Diarrheals, Proton Pump Inhibitors, Histamine Blockers, Growth Hormone, Glucagon-like Peptide, and Others By Distribution Channel - Specialty Pharmacies, Hospital Pharmacies, and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Short Bowel Syndrome Market report based on drug type, distribution channel, and region.

Short Bowel Syndrome Market, By Drug Type:

• Anti-Diarrheals
• Proton Pump Inhibitors
• Histamine Blockers
• Growth Hormone
• Glucagon-like Peptide
• Others

Short Bowel Syndrome Market, By Distribution Channel:

• Specialty Pharmacies
• Hospital Pharmacies
• Others

Short Bowel Syndrome Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Short Bowel Syndrome Market includes, Shire Plc, Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Swedish Orphan Biovitrum AB, Merck & Company, Inc., Pfizer Inc., Novartis AG, Mylan N.V., Johnson & Johnson and others.

Recent Development:

• In December 2023, Zealand Pharma A/S), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS) dependent on parenteral support.
• In October 2023, Ironwood Pharmaceuticals, Inc., a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week. This multicenter study of nine patients was designed to evaluate the safety, pharmacokinetics, and efficacy of apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog, on intestinal absorption in adult patients who have Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC). Positive interim results from this study were first announced in October 2022.

• Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Shire Plc
• AstraZeneca Plc
• Swedish Orphan Biovitrum AB
• Merck & Company Inc.
• Pfizer Inc
• Novartis AG
• Mylan N.V.
• Johnson & Johnson

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Preview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Type
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Opportunity Map
3. Market Dynamics
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
     • Drivers- Restraints Impact Analysis
     • PEST Analysis
     • Porter’s Five Forces Analysis
4. Market Segmenataion, By Drug Type, 2024 – 2034, (US$ Mn)
   • Introduction
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2018 — 2028
     • Y-o-Y Growth Analysis (%), 2019 – 2028
     • Segment Trends
   • Anti-Diarrheals
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Proton Pump Inhibitors
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Histamine Blockers
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Growth Hormone
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Glucagon-like Peptide
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Others
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
5. Market Segmenataion, By Distribution Channel, 2024 – 2034, (US$ Mn)
   • Introduction
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2018 — 2028
     • Y-o-Y Growth Analysis (%), 2019 – 2028
     • Segment Trends
   • Specialty Pharmacies
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
   • Others
     • Introduction
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2024 – 2034
6. Global Market, By Region, 2024 – 2034, (US$ Mn)
   • Introduction
     • Market Share Analysis, By Region, 2018 and 2028(%)
     • Y-o-Y Growth Analysis, For Regions, 2019–2028
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Mn), By Drug Type, 2024 – 2034
     • Market Size and Forecast (US$ Mn), By Distribution Channel, 2024 – 2034
     • Market Size and Forecast, By Country, 2024 – 2034, (US$ Mn)

Ø  U.S.

Ø  Canada

1. Latin America
   • Market Size and Forecast (US$ Mn), By Drug Type, 2024 – 2034
   • Market Size and Forecast (US$ Mn), By Distribution Channel, 2024 – 2034
   • Market Size and Forecast, By Country, 2024 – 2034, (US$ Mn)

Ø  Brazil

Ø  Mexico

Ø  Argentina and Chile

Ø  Rest of Latin America

1. Europe
   • Market Size and Forecast (US$ Mn), By Drug Type, 2024 – 2034
   • Market Size and Forecast (US$ Mn), By Distribution Channel, 2024 – 2034
   • Market Size and Forecast, By Country, 2024 – 2034, (US$ Mn)

Ø  Germany

Ø  UK

Ø  France

Ø  Russia

Ø  Italy

Ø  Switzerland

Ø  Sweden

Ø  Rest of Europe

1. Asia Pacific
   • Market Size and Forecast (US$ Mn), By Drug Type, 2024 – 2034
   • Market Size and Forecast (US$ Mn), By Distribution Channel, 2024 – 2034
   • Market Size and Forecast, By Country, 2024 – 2034, (US$ Mn)

Ø  China

Ø  India

Ø  Australia & New Zealand

Ø  Japan

Ø  South Korea

Ø  Rest of Asia Pacific

1. Middle East
   • Market Size and Forecast (US$ Mn), By Drug Type, 2024 – 2034
   • Size and Forecast, By Distribution Channels, 2024 – 2034, (US$ Mn)
   • Market Size and Forecast, By Country, 2024 – 2034, (US$ Mn)

Ø  GCC

Ø  Israel

Ø  Saudi Arabia

Ø  UAE

Ø  Rest of Middle East

1. Africa
   • Market Size and Forecast (US$ Mn), By Drug Type, 2024 – 2034
   • Market Size and Forecast (US$ Mn), By Distribution Channel, 2024 – 2034
   • Market Size and Forecast, By Country, 2024 – 2034, (US$ Mn)

Ø  South Africa

Ø  Central Africa

Ø  North Africa

1. Competitive Landscape
   • Heat Map Analysis
   • Company Profiles
     • Shire Plc*

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Teva Pharmaceutical Industries Ltd.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • AstraZeneca Plc

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Swedish Orphan Biovitrum AB

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Merck & Company, Inc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Pfizer Inc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Novartis AG

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Mylan N.V.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1.  
   • Johnson & Johnson

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

1. Analyst Views
2. Section
   • Research Methodology
   • About Us
   • Contact